Kovaltry
octocog alfa · Bayer AG
AUTHORISED IN THE EUWhat Kovaltry is used for
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Kovaltry
- Active substance
- octocog alfa
- Disease area
- Hemophilia A
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD02
- Marketing authorisation holder
- Bayer AG
- Authorised in the EU since
- 2016
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kovaltry used for?
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.
What is the active substance in Kovaltry?
Kovaltry contains octocog alfa.
Who makes Kovaltry?
The EU marketing authorisation holder is Bayer AG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU